AMAnne Marie Rosendahl Madsen

Anne Marie Rosendahl Madsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne Marie Rosendahl Madsen has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • Christine Stabell Benn

    Bandim Health Project, OPEN, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau; Danish Institute for Advanced Study, University of Southern Denmark, Odense, Denmark

    5 shared publications
  • Peter Aaby

    Southern Danish University

    4 shared publications
  • Sebastian Nielsen

    Bandim Health Project, Bissau, Guinea-Bissau

    4 shared publications
  • Christian Backer Mogensen

    Department of Emergency Medicine, University hospital of Southern Denmark, Aabenraa, Denmark

    2 shared publications
  • Ellen Christine Leth Loekkegaard

    Department of Gynecology and Obstetrics, Nordsjaelland Hospital, Copenhagen University Hospital , Hilleroed , Denmark

    2 shared publications
  • Frederik Schaltz-Buchholzer

    Bandim Health Project, Open Patient Data Explorative Network (OPEN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Bandim Health Project, INDEPTH Network, 8611004 Bissau, Guinea-Bissau

    2 shared publications

Latest Publications

  • Open Access

    Evaluating the non-specific effects of BCG vaccination on the immune system and serological response to influenza vaccination in the elderly: A randomised controlled trial

    by Anne Marie Rosendahl Madsen, Frederik Schaltz-Buchholzer, Ramona Trebbien, Rutger Roring, Nina Bang, Christian Nielsen, Mette Bliddal, Lene Annette Norberg, Mihai G. Netea, Torben Barington, et al.


  • Open Access

    The effect of BCG vaccination on adult mortality during the COVID-19 pandemic: a meta-analysis of randomised controlled trials

    by Frederik Schaltz-Buchholzer, Nigel Curtis, Andreas H. Diacon, Evangelos J. Giamarellos-Bourboulis, Antigone Kotsaki, Anne Marie Rosendahl Madsen, Nicole L. Messina, Lidia Nhamússua, Sebastian Nielsen, Laure F. Pittet, et al.

    Objectives: Bacillus Calmette-Guérin (BCG), similar to some other live vaccines, may offer partial protection against unrelated infections. During the COVID-19 pandemic, several trials tested whether BCG provides protection against COVID-19. Design: Meta-analysis of randomised placebo-controlled trials which provided mortality data. Setting: High-income settings as well as low- and middle-income settings (LMICs). Participants: Trial populations were healthcare workers (HCW) or individuals of older age, followed for 6-12 months. Interventions: BCG vaccine versus placebo. Main outcome measure: Overall mortality and COVID-19 mortality. Results: Nine of the 15 RCTs reported at least one death. Trial populations were healthcare workers (4 RCTs) or individuals of older age (5 RCTs), in Europe (5 RCTs) or LMICs (4 RCTs) with a total of 8,169 participants randomly allocated to BCG (18 deaths) and 8,176 to placebo (37 deaths). In a meta-analysis, receiving BCG vs placebo was associated with a 51% (95% CI: 15 to72%) reduction in all-cause mortality. The all-cause mortality RRR was 78% (−3 to 95%) in HCWs (Europe and LMICs) and 43% (95% CI: −6 to 69%) in the elderly. It was 37% (95 CI: −15 to 66%) in Europe and 90% (95% CI: 22 to 99%) in LMICs. The relative reduction of deaths (6 BCG; 12 placebo) from COVID-19 was 50% (95 CI: −33 to 81). Conclusions: BCG may have reduced all-cause mortality in the context of the COVID-19 pandemic.


  • Open Access

    Evaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: A randomised clinical trial

    by Anne Marie Rosendahl Madsen, Lise Gehrt, Frederik Schaltz-Buchholzer, Sören Möller, Rikke Christiansen, Lars Schellerup, Lene Annette Norberg, Tyra Grove Krause, Sebastian Nielsen, Mette Bliddal, et al.


  • Open Access

    Using BCG Vaccine to Enhance Nonspecific Protection of Health Care Workers During the COVID-19 Pandemic: A Randomized Controlled Trial

    by Anne Marie Rosendahl Madsen, Frederik Schaltz-Buchholzer, Sebastian Nielsen, Thomas Benfield, Morten Bjerregaard-Andersen, Lars Skov Dalgaard, Christine Dam, Sisse Bolm Ditlev, Gulia Faizi, Mihnaz Azizi, et al.

    Background: The BCG (Bacillus Calmette-Guérin) vaccine can induce nonspecific protection against unrelated infections. We aimed to test the effect of BCG on absenteeism and health of Danish health care workers (HCWs) during the coronavirus disease 2019 (COVID-19) pandemic. Methods: A single-blinded randomized controlled trial included 1221 HCWs from 9 Danish hospitals. Participants were randomized 1:1 to standard dose BCG or placebo. Primary outcome was days of unplanned absenteeism. Main secondary outcomes were incidence of COVID-19, all-cause hospitalization, and infectious disease episodes. Results: There was no significant effect of BCG on unplanned absenteeism. Mean number of days absent per 1000 workdays was 20 in the BCG group and 17 in the placebo group (risk ratio, 1.23; 95% credibility interval, 0.98–1.53). BCG had no effect on incidence of COVID-19 or all-cause hospitalization overall. In secondary analyses BCG revaccination was associated with higher COVID-19 incidence (hazard ratio [HR], 2.47; 95% confidence interval [CI], 1.07–5.71), but also reduced risk of hospitalization (HR, 0.28; 95% CI, .09–.86). The incidence of infectious disease episodes was similar between randomization groups (HR, 1.09; 95% CI, .96–1.24). Conclusions: In this relatively healthy cohort of HCWs, there was no overall effect of BCG on any of the study outcomes. Clinical Trials Registration: NCT0437329 and EU Clinical Trials Register (EudraCT number 2020-001888-90).


  • Open Access

    Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark

    by Anne Marie Rosendahl Madsen, Frederik Schaltz-Buchholzer, Thomas Benfield, Morten Bjerregaard-Andersen, Lars Skov Dalgaard, Christine Dam, Sisse Bolm Ditlev, Gulia Faizi, Isik Somuncu Johansen, Poul-Erik Kofoed, et al.

    Objectives: The Bacille Calmette-Guérin (BCG) vaccine against tuberculosis is associated with non- specific protective effects against other infections, and significant reductions in all-cause morbidity and mortality have been reported. We aim to test whether BCG vaccination may reduce susceptibility to and/or the severity of COVID-19 and other infectious diseases in health care workers (HCW) and thus prevent work absenteeism.The primary objective is to reduce absenteeism due to illness among HCW during the COVID-19 pandemic. The secondary objectives are to reduce the number of HCW that are infected with SARS-CoV-2, and to reduce the number of hospital admissions among HCW during the COVID-19 pandemic.Hypothesis: BCG vaccination of HCW will reduce absenteeism by 20% over a period of 6 months.Trial design: Placebo-controlled, single-blinded, randomised controlled trial, recruiting study participants at several geographic locations. The BCG vaccine is used in this study on a different indication than the one it has been approved for by the Danish Medicines Agency, therefore this is classified as a phase III study.Participants: The trial will recruit 1,500 HCW at Danish hospitals.To be eligible for participation, a subject must meet the following criteria: Adult (≥18 years); Hospital personnel working at a participating hospital for more than 22 hours per week.A potential subject who meets any of the following criteria will be excluded from participation in this study: Known allergy to components of the BCG vaccine or serious adverse events to prior BCG administration Known prior active or latent infection with Mycobacterium tuberculosis (M. tuberculosis) or other mycobacterial species Previous confirmed COVID-19 Fever (>38 C) within the past 24 hours Suspicion of active viral or bacterial infection Pregnancy Breastfeeding Vaccination with other live attenuated vaccine within the last 4 weeks Severely immunocompromised subjects. This exclusion category comprises: a) subjects with known infection by the human immunodeficiency virus (HIV-1) b) subjects with solid organ transplantation c) subjects with bone marrow transplantation d) subjects under chemotherapy e) subjects with primary immunodeficiency f) subjects under treatment with any anti-cytokine therapy within the last year g) subjects under treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months h) Active solid or non-solid malignancy or lymphoma within the prior two years Direct involvement in the design or the execution of the BCG-DENMARK-COVID trial Intervention and comparator: Participants will be randomised to BCG vaccine (BCG-Denmark, AJ Vaccines, Copenhagen, Denmark) or placebo (saline). An adult dose of 0.1 ml of resuspended BCG vaccine (intervention) or 0.1 ml of sterile 0.9% NaCl solution (control) is administered intradermally in the upper deltoid area of the right arm. All participants will receive one injection at inclusion, and no further treatment of study participants will take place.Main outcomes: Main study endpoint: Days of unplanned absenteeism due to illness within 180 days of randomisation.Secondary study endpoints: The cumulative incidence of documented COVID-19 and the cumulative incidence of hospital admission for any reason within 180 days of randomisation.Randomisation: Randomisation will be done centrally using the REDCap tool with stratification by hospital, sex and age groups (+/- 45 years of age) in random blocks of 4 and 6. The allocation ratio is 1:1.Blinding (masking): Participants will be blinded to treatment. The participant will be asked to leave the room while the allocated treatment is prepared. Once ready for injection, vaccine and placebo will look similar, and the participant will not be able to tell the difference.The physicians administering the treatment are not blinded.Numbers to be randomised (sample size): Sample size: N=1,500. The 1,500 participants will be randomised 1:1 to BCG or placebo with 750 participants in each group.Trial Status: Current protocol version 5.1, from July 6, 2020.Recruitment of study participants started on May 18, 2020 and we anticipate having finished recruiting by the end of December 2020.Trial registration: The trial was registered with EudraCT on April 16, 2020, EudraCT number: 2020-001888-90, and with ClinicalTrials.gov on May 1, 2020, registration number NCT04373291.Full protocol: The full protocol is attached as an additional file, accessible from the Trialswebsite (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.Keywords: COVID-19, Randomised controlled trial, Protocol, BCG vaccine, NSEs/Non-specific effects of vaccines, Heterologous effects of vaccines, Health care workers, Pandemic, Immune training.


  • Open Access

    Prevalence and significance of Mycoplasma genitalium in women living with HIV in Denmark

    by Anne Marie Rosendahl Madsen, Kristina Thorsteinsson, Anne-Mette Lebech, Merete Storgaard, Terese L. Katzenstein, Frederikke F. Rönsholt, Isik Somuncu Johansen, Gitte Pedersen, Lars Noerregaard Nielsen, Aase Bengaard Andersen, et al.

    Mycoplasma genitalium (M. genitalium) is a sexually transmitted pathogen associated with urethritis, cervicitis, and pelvic inflammatory disease. Previous studies have shown a strong association between M. genitalium and HIV infection, therefore screening and treatment for M. genitalium has been suggested as part of HIV prevention strategies. The objective of this study was to determine the prevalence of M. genitalium in women living with HIV (WLWH) in Denmark, and to compare the result with data on symptoms from the lower abdomen, sexual habits and immune status. 234 women, recruited from Danish HIV centres as part of a larger observational study on aspects of living with HIV as a woman (the SHADE study), were included. We tested cervical samples for M. genitalium by specific PCR. We found three samples positive (1.3%). The women were between 30 and 50 years old, all were of Asian origin, sexually active, and on antiretroviral treatment with supressed HIV RNA and CD4 count >350 cells/µL. None reported symptoms from the lower abdomen. The prevalence of M. genitalium infection in WLWH in Denmark is low, thus systematic screening for M. genitalium in this group does not seem relevant.


  • Whole-genome sequencing for identification of the source in hospital-acquired Legionnaires' disease

    by A.M. Rosendahl Madsen, A. Holm, T.G. Jensen, E. Knudsen, H. Lundgaard, M.N. Skov, S.A. Uldum, M. Kemp